ALKS - Alkermes plc
| Previous Close | 17.61 |
| Open | 17.64 |
| Bid | 18.04 x 800 |
| Ask | 18.05 x 1800 |
| Day's Range | 17.54 - 18.31 |
| 52 Week Range | 16.65 - 37.75 |
| Volume | 362,695 |
| Avg. Volume | 1,588,829 |
| Market Cap | 2.871B |
| Beta (5Y Monthly) | 2.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.25 |
| Earnings Date | Apr 22, 2020 - Apr 26, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.75 |
- Thomson Reuters StreetEvents
Edited Transcript of ALKS earnings conference call or presentation 13-Feb-20 1:00pm GMT
Q4 2019 Alkermes Plc Earnings Call
- Zacks
Alkermes' (ALKS) Earnings and Revenues Beat Estimates in Q4
Alkermes (ALKS) beats earnings and sales estimates in the fourth quarter of 2019.
- Barrons.com
Alkermes Reported More Revenue Than Expected. Here’s Why the Stock Is Falling.
It looks like investors may be running out of patience with Alkermes, a biotech with drugs on the market to treat alcohol dependence and schizophrenia.
- Zacks
Alkermes (ALKS) Tops Q4 Earnings and Revenues Beat Estimates
Alkermes beats earnings and sales estimates in the fourth quarter of 2019.
- Zacks
Alkermes (ALKS) Q4 Earnings and Revenues Top Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of 25.76% and 1.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Benzinga
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: ...
- PR Newswire
Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020
Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2019 and provided financial expectations for 2020.
- MoneyShow
Alkermes Targets Bipolar Disorder and Schizophrenia
We strongly recommend that investors take advantage of the weakness and buy Alkermes (ALKS), explains John McCamant, biotech sector expert and editor of The Medical Technology Stock Letter.
- Zacks
Alkermes (ALKS) to Report Q4 Earnings: What's in Store?
We expect Alkermes (ALKS) to provide revenue updates on its proprietary marketed products and pipeline candidates when it releases fourth-quarter earnings on Feb 13.
- PR Newswire
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 13, 2020, to discuss the company's fourth quarter and year-end 2019 financial results. Management will also discuss financial expectations for 2020 and provide an update on the company.
- Zacks
Alkermes (ALKS) to Report Q4 Results: Wall Street Expects Earnings Growth
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review
The FDA accepts for review Alkermes' (ALKS) NDA for ALKS 3831 for the treatment of schizophrenia and bipolar I disorder and has set an action date of Nov 15, 2020.
- PR Newswire
Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder
Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) seeking approval of ALKS 3831 (olanzapine/samidorphan) for the treatment of schizophrenia and for the treatment of bipolar I disorder. ALKS 3831 is an investigational, novel, once-daily, oral atypical antipsychotic drug candidate designed to provide the efficacy of olanzapine while mitigating olanzapine-associated weight gain. The NDA has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of Nov. 15, 2020.
- Zacks
Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Alkermes (ALKS) closed at $19.99, marking a -0.05% move from the previous day.
- Insider Monkey
Hedge Fund Favorites vs. Alkermes Plc (ALKS) In 2019
2018's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the […]
- Simply Wall St.
Does Alkermes plc (NASDAQ:ALKS) Have A High Beta?
If you own shares in Alkermes plc (NASDAQ:ALKS) then it's worth thinking about how it contributes to the volatility of...
- Zacks
Alkermes (ALKS) Gains As Market Dips: What You Should Know
Alkermes (ALKS) closed the most recent trading day at $19.52, moving +1.61% from the previous trading session.
- PR Newswire
Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference
Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2020 at 9:00 a.m. PT (12:00 p.m. ET/5:00 p.m. GMT) from the Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session that will begin at 9:30 a.m. PT (12:30 p.m. ET/5:30 p.m. GMT).The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
- Zacks
LGND vs. ALKS: Which Stock Is the Better Value Option?
LGND vs. ALKS: Which Stock Is the Better Value Option?
- Zacks
Alnylam Stock Up More Than 61% YTD on Pipeline Progress
Shares of Alnylam (ALNY) rise on significant pipeline progress.
- Zacks
Flexion's (FLXN) Stock Up on FDA Approval for Zilretta sNDA
Flexion's (FLXN) sNDA for osteoarthritis drug, Zilretta, seeking removal of confusing limitation of use label, gets FDA approval.
- Zacks
Seattle Genetics Submits NDA to FDA for Tucatinib Combo
Seattle Genetics (SGEN) submits an NDA to the FDA for tucatinib in combination with Herceptin and Xeloda seeking approval to treat locally advanced/metastatic HER2-positive breast cancer.
- Zacks
All You Need to Know About Alkermes (ALKS) Rating Upgrade to Strong Buy
Alkermes (ALKS) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
